MedTrace Logo

Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

NCT06781567 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2025-03-14

No results posted yet for this study

Summary

This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.

Conditions

Interventions

DRUG

HG146

HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Sponsors & Collaborators

  • HitGen Inc.

    lead INDUSTRY

Principal Investigators

  • Ye Guo · Shanghai Oriental Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-13
Primary Completion
2028-12-31
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06781567 on ClinicalTrials.gov